If treatment with steroids fails (steroid-refractory GvHD), then patients should be started on ruxolitinib, a JAK1/2 inhibitor which suppresses inflammatory signaling by cytokines involved in GvHD pathophysiology [34]. Here, JAK1 is linked to graft versus host disease.